The management of the University of Óbuda sanctified another promising corporate cooperation. This time a cooperation agreement was signed with DiabTrend AI Analytics Ltd. The common goal is to develop a world-class decision support system for diabetics that can be sold on the world market by combining the competencies, resources and innovative solutions of the two Parties.
Prof. Rector Dr. Levente Kovács thanked the company’s management for the commitment he showed from the beginning to the University of Óbuda in connection with the cooperation started in the Cyber Medicine Competence Center (KIKOK) tender. He reminded that research on diabetes at the University of Óbuda goes back a decade. The rector recalled that his research on the subject was carried out, among others, with the participation of the Hungarian Diabetes Society, whose working group dealing with artificial pancreas was recently established at the end of last year.
As a Hungarian startup company, DiabTrend Ltd. combines the possibilities provided by modern personal IT devices with the use of the latest sensors and artificial intelligence methods in order to facilitate the daily life of diabetics. During their development, in addition to their own technologies, they also integrate the results of the University of Óbuda’s scientific workshop into their mobile application, which provides services such as semi-automatic logging, blood glucose forecasting and various automatic alerts for diabetics and care professionals.
All this is clearly related to the ideas expressed in the field of Medicina 4.0. Prof. Dr. Levente Kovács called the ideas born in the meantime both from an educational and research point of view, which were shared with the leaders of DiabTrend Kft. and they were born in consultation with Dr. György Eigner , director of the Institute of Biomatics and Applied Artificial Intelligence, and Dr. Péter Galambos , director of the Cyber Medicine Competence Center (KIKOK) of the University of Óbuda, ie the participants of the work program. He expressed the hope that the formally established cooperation would lay the foundation for the long-term continuation of the joint work.
Marcell Havlik , CEO of DiabTrend AI Analytics Ltd., expressed his joy at the establishment of the cooperation. He stressed that the leadership of the University was extremely positive about joint innovation. Their company is committed to working with university researchers to create marketable products, as their experience has great potential for synergies between academic research and market-oriented development.
The cooperation agreement was signed by DiabTrend AI Analytics Kft.: Marcell Havlik, Managing Director, Tamás Havlik, Chief Technology Officer, and Prof. Dr. Levente Kovács, Rector and Gabriella Ormándi , Chancellor.
The event was also attended by Dr. Péter Galambos, Director of the Cyber Medicine Competence Center (KIKOK) of the University of Óbuda and Dr. György Eigner, Director of the Institute of Biomatics and Applied Artificial Intelligence.
More details about the collaboration
The aim of the cooperation is to develop a world-class decision support system for diabetics that can be sold on the world market by combining the competencies, resources and innovative solutions of the two Parties.
On the part of the University, the cooperation takes place within the framework of the project “Establishment of an innovation service base for the development of cyber-medical systems for diagnostic, therapeutic and research purposes” (hereinafter KIKOK project) with the identification number “2019-1-3-1-KK-2019-00007”, with the intention that the University intends to maintain the cooperation after the implementation and maintenance period of the project, if this is possible in a mutually beneficial way for both parties.
The basic goal of cooperation
The Parties shall share with each other their theoretical and practical knowledge base, their network of contacts, the use of their own solutions in order to achieve their professional and market objectives.
Both Parties are determined to develop a unique and innovative product or group of products that can be sold on the world market. The primary goal of the collaboration is to make emerging products a global leader in decision support for diabetics by making them accessible to each other.
Another objective is to increase the Parties’ innovation potential through the implementation of joint research and development activities.
The Parties also intend to cooperate in launching and implementing joint domestic and international tender and project activities.